Pharmaceutical Roots-The origins of aspirin: May 2021 edition

Microbioz India, May , 2021 Issue

Cover Story : "Pharmaceutical Roots-The origins of aspirin: May 2021 edition"

Pharmaceutical Roots-The origins of aspirin: May 2021 edition

Aspirin is a salicylate (sa-LIS-il-ate). It works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation. It is sometimes used to treat or prevent heart attacks, strokes, and chest pain (angina). There is evidence that has shown that aspirin as a chemoprotective agent may reduce overall cancer incidence and mortality in colorectal, esophageal and gastric cancers with smaller effects on prostate, breast and lung cancer. The cover story of this month titled: “Pharmaceutical Roots: The origins of aspirin” authored by Dulcie Phipps is an Assistant Global Product Manager at LGC. As the story suggests Pharmaceutical roots are a new content series from LGC Mikromol, investigating and outlining the natural origins of pharmaceutical substances, and offering a deeper dive into their uses, risks, and mechanisms of action.


What have we learned from the nitrosamine crisis?

The pharmaceutical industry is facing an ongoing issue with genotoxic impurities (GTIs). Over the past year, we have witnessed genotoxic impurities affect several drugs, including those used to treat elevated blood pressure, heartburn and acid reflux.Read more

Renishaw introduces the world’s first Raman system with remote probes capable of focus-tracking

Renishaw’s latest version of its Virsa™ Raman analyser, with new WiRE™ 5.5 software, enables its users to analyse samples away from the confines of the laboratory microscope, using remote fibre-optic probes.Read more..

GenNext Technologies Announces NIH Grant Funding of Nearly $7M Leads to a Seminal Protein Footprinting Patent

GenNext Technologies, Inc., a growth-stage company that provides instrumentation, software, and services to structural biology researchers within the Read more…

Cipla enters into a licensing agreement with MSD

Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has signed a non-exclusive licensing agreement with MSD a tradename of Merck & Co., Inc. Read more.